THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Life Sciences: Pharmaceuticals

SEC focusing on drug makers

Full disclosure of tests called key

By Jeffrey Krasner
Globe Staff / September 27, 2004

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

  • E-mail|
  • Print|
  • Reprints|
  • |
Text size +

The Securities and Exchange Commission is scrutinizing biotechnology companies as part of a wider effort to ensure that companies don't mislead investors by covering up negative results of clinical trials. (Full Article: 820 Words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 Article
  • $9.95 4 Articles
  • $99.95 Unlimited